Notice: Undefined variable: post_type in /home/egfrcanc/public_html/wp-content/plugins/all-in-one-seo-pack/aioseop_class.php on line 4249
14 March 2019

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon 

2019-03-14T10:04:41-07:00

*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon 2019-03-14T10:04:41-07:00
3 February 2019

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

2019-02-03T11:06:16-07:00

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC2019-02-03T11:06:16-07:00
5 January 2019

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?

2019-01-05T11:08:03-07:00

*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer.

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?2019-01-05T11:08:03-07:00